TVRD Tvardi Therapeutics4.61+1.51 (+48.7%)
Premarket Decliner
TVRD Tvardi Therapeutics41.60-1.38-3.2%
Premarket:7.50-34.10 (-82.0%)
Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis
Business WireMon, 13-Oct 7:30 AM
